Kevin Wu

Kevin Wu, MD, serves as Executive Director at Schrödinger since May 2024, following a tenure as Senior Medical Director at AbbVie from March 2021 to May 2024, where responsibilities included research on Lemzoparlimab combinations for various hematological malignancies and Ibrutinib phase 3 studies in relapsed lymphomas. Prior to AbbVie, Kevin worked at AstraZeneca as Senior Medical Director and Clinical Development Lead, overseeing trials for Durvalumab in non-small cell lung cancer and head/neck cancers. Earlier experience includes roles as Medical Director of Thoracic Oncology at Novartis, Assistant Professor of Clinical Medicine at Indiana University South Bend, and participation in a multidisciplinary team at Memorial Hospital of South Bend. Kevin's foundational training includes a Physician Fellowship in Hematology Oncology at New York Presbyterian Hospital, residency at Keck Medicine of USC, and an MD from UC San Diego. Kevin also holds board certifications in Internal Medicine and Medical Oncology.